Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 4/20 | 0.78 |
| ▸ | SRC | P12931 | 3/20 | 0.62 |
| ▸ | RAF1 | P04049 | 7/20 | 0.60 |
| ▸ | BRAF | P15056 | 5/20 | 0.60 |
| ▸ | KDR | P35968 | 4/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.58 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.58 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.57 |
| ▸ | EGFR | P00533 | 5/20 | 0.56 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485078 | 0.88 | FGFR2 (1.00) | FGFR2SRCRAF1KDRMAP2K1 | |
| SCHEMBL4478724 | 0.88 | FGFR2 (1.00) | FGFR2SRCRAF1KDRMAP2K1 | |
| SCHEMBL29631554 | 0.84 | SRC (0.60) | FGFR2SRCRAF1BRAFKDR | |
| SCHEMBL7209612 | 0.84 | EGFR (0.62) | FGFR2SRCRAF1BRAFKDR | |
| SCHEMBL4471428 | 0.84 | FGFR2 (0.70) | FGFR2RAF1BRAFKDREGFR | |
| SCHEMBL4476247 | 0.84 | FGFR2 (0.92) | FGFR2SRCRAF1KDRMAP2K1 | |
| SCHEMBL4465059 | 0.83 | FGFR2 (0.91) | FGFR2SRCKDRMAP2K1EGFR | |
| SCHEMBL5824844 | 0.81 | KDR (0.69) | SRCRAF1BRAFKDREGFR | |
| SCHEMBL17278095 | 0.80 | BRAF (0.70) | SRCRAF1BRAFKDREGFR | |
| SCHEMBL23720684 | 0.80 | FLT4 (0.60) | BRAFKDREPHA2EPHB4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | claimed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | FGFR1, FGFR2, FGFR3 | FGFR2 2/4885SRC 30/4885RAF1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.